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BP  =  Bodily pain 
CK   = CyberKnife 
GH   = General health 
GJT   = Glomus jugulare tumor  
GJTs   = Glomus jugulare tumors 
GK   = GammaKnife 
HC   = Health concepts 
LC   = Local control 
LINAC  = Linear accelerator 
MH   = Mental health 
MV   = Megavolt 
PD   = Progressive disease 
PF   = Physical functioning 
Qol   = Quality of life 
RE   = Role emotional  
RP   = Role physical 
RRS   = Robotic radiosurgery 
RS   = Radiosurgery  
SF   = Social functioning 
VT   = Vitality  
WHO  = World Health Organization 
  




I. Single-Session Image-Guided Robotic Radiosurgery and Quality of Life for Glomus 
Jugulare Tumors1 
 
II. Image-Guided Robotic Radiosurgery for Glomus Jugulare Tumors – Multicenter 
Experience and Review of the Literature2 
  




I, Felix Ehret, was the first author and principal investigator of both publications of this 
cumulative dissertation1,2. No shared first authorships were applied. I was responsible for the 
study design, planning, literature search, literature review, data collection, data analysis, data 
monitoring, data interpretation, tables, figures, first manuscript drafts, writing, editing, final 
editing, submission process and revisions for both studies. Co-authors of both studies were 
partly involved in the data collection, data interpretation and final editing of the publications. 
  




According to the WHO, paragangliomas are vascular, mostly benign, extra-adrenal tumors of 
sympathetic or parasympathetic paraganglia origin, which can arise in various locations 
throughout the body3. This tumor entity is closely related to the pheochromocytoma, which 
is defined as an intra-adrenal paraganglioma3. Genetic alterations cause a significant proportion 
of paragangliomas and common tumor sites include the head, neck, thorax, abdomen, pelvis 
and the adrenal glands in case of pheochromocytomas4. Paragangliomas deriving from the 
adventitial chemoreceptor tissue of the jugular bulb are commonly known as glomus jugulare 
tumors (GJTs). This term was initially coined by the anatomy professor Stacy Guild from Johns 
Hopkins University in 19415. Before, these tumors were labeled as a ganglion by Valentin in 
18406. With an estimated incidence of one per 1.3 million, GJTs are rare tumors and they only 
account for a minor proportion of all head and neck tumors7. GJTs grow in direct proximity 
of the jugular foramen, close to the cranial nerves IX, X, XI, the temporal bone and the internal 
jugular vein. Even though GJTs are considered to be benign tumors, they are capable of locally 
infiltrating surrounding tissue8. Thus, common symptoms of GJTs include lower cranial nerve 
disorders and range from pulsatile tinnitus, vertigo, hearing loss, dysphagia, dysarthria to – in 
catecholamine-secreting tumors – cardiovascular complications like tachycardia or 
hypertension. Hence, the quality of life (Qol) can be significantly decreased in patients with 
head and neck paragangliomas or GJTs, respectively9-11. Rarely, GJTs can metastasize to local 
lymph nodes or distant organs8,12-16. Malignant GJTs account for approximately 3% of tumors8,12. 
In 1934, Seiffert conducted the first reported surgical resection of a glomus jugulare tumor 
(GJT)17. Since then and until the development of radiotherapy, the primary treatment option 
for GJTs was the surgical resection. Due to the tumor’s high vascularization and localization 
near the skull base and large vessels, surgical procedures may cause severe complications, 
including posttreatment cranial nerve dysfunctions and, occasionally, significant blood loss due 
to cerebrovascular injuries, as well as strokes18-25. Despite the recent advancements in surgery, 
the microsurgical tumor extirpation still yields considerable morbidity for patients even if 
preoperative embolization procedures to reduce the intraoperative bleeding risk are 
performed19,20,25. Non-invasive treatment options came to the fore to overcome this 
treatment-associated morbidity. 
With radiotherapy becoming more and more available since the 1970s, radiation oncologists 
started to investigate fractionated radiotherapy for head and neck paragangliomas and GJTs. 
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Radiotherapy studies throughout the past decades reported high local control (LC) rates, 
usually around 90%, with a more favorable risk profile than surgery10,19,25-36. Yet, external body 
radiotherapy can be associated with radiation-induced complications when doses of 55 to 65 
Gy are applied25. Usually, doses of 45 Gy over 25 fractions are well-tolerated and have a low 
risk of complications19. Fractionated radiotherapy soon became a recognized treatment 
alternative to surgery. 
To reduce treatment length and field sizes, radiosurgery (RS) was of interest since 
radiosurgical treatment modalities became more and more available. In 1995, Kida and 
colleagues firstly reported on the use of RS to treat two GJTs and four lower cranial 
neurinomas37. Since then, numerous retrospective studies have investigated radiosurgical 
treatments for GJTs throughout the past three decades. Considering the rarity of the tumor, 
consensus guidelines and large prospective trials with long-term follow-up are not available19,25. 
Most of the radiosurgical work was done with the GammaKnife (GK), a stereotactic treatment 
unit which was developed by the Swedish neurosurgeon Lars Leksell2,38,39. Notably, the GK is 
limited to the treatment of cranial lesions due to its design and construction. Thus, tumors 
extending to the lower neck or extracranial neoplasms cannot be treated. Besides, linear 
accelerator (LINAC)-based radiosurgical treatments and fractionated radiotherapy outcomes 
were investigated as well, whereas only a few studies analyzed image-guided robotic 
radiosurgery (RRS) for the treatment of GJTs1,2,19. This radiosurgical tool was developed by 
the neurosurgeon John Adler at Stanford University in the 1990s40. The device utilizes a 
robotic arm which carries a small 6 megavolt (MV) LINAC and can freely move around the 
patient. No stereotactic frame is needed for treatment delivery. This enables the user to 
perform frameless stereotactic RS, which is capable of irradiating cranial as well as extracranial 
tumors40. Today, it is built by the Californian company Accuray Incorporated and is commonly 
known under the name “CyberKnife” (CK). As the reported data for the use of RRS for GJTs 
is heterogeneous and relatively limited, the overall objective of this thesis was to define and 
analyze the role of primary and secondary RRS in the management of GJTs and to report 
essential outcomes for local tumor control, symptom control, radiographic tumor changes 
and Qol after treatment delivery. To achieve this objective, two dedicated studies were 
conducted1,2. Both publications of this cumulative dissertation were strictly limited to GJTs, 
which were either histologically proven after biopsy or surgery or the clinical appearance, as 
well as the imaging findings were sufficient for GJT diagnosis. Moreover, to categorize and 
assess the respective findings, a comprehensive literature review was done for the use of RS 
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and RRS for GJTs. Finally, the limitations of both publications regarding study design and data 
quality were discussed.  
Publication I 
The first publication investigated the monocentric experience of RRS for GJTs at the European 
CyberKnife Center Munich1. Over a period of 13 years, 53 patients were retrospectively 
included in the analysis1. Thirty-three of them underwent primary treatment with RRS1. This 
study analyzed the outcomes and Qol data after single-session RRS1. The results show that 
RRS is a safe, reliable and efficient tool for the primary and secondary treatment of GJT1. After 
a median follow-up of 38 months, an overall LC of 98% was achieved1. Only one of the 53 
patients developed a local recurrence1. The literature review for RRS showed that most of 
the reported data is heterogeneous and many studies included not only GJTs but also other 
paragangliomas, e.g. glomus jugulotympanicum, glomus tympanicum and carotid body tumors, 
in their analyses1. The clinical outcomes were comparable with other radiosurgical studies, as 
most of the patients experienced symptom control or pretreatment deficit improvements1,2. 
LC rates were as high as reported elsewhere in the literature1,19,25. To the best of our 
knowledge, this was the first study to report standardized Qol data before and after treatment 
delivery1. So far, only a few studies have investigated the Qol in head and neck paragangliomas, 
including GJTs, most of them by mailing questionnaires after treatment delivery11,41,42. In the 
first publication, the Qol was measured by the SF-12, the shortened version of the SF-3643,44. 
The SF-12 is a well-established and validated questionnaire to assess the Qol for eight different 
health concepts (HC)43-45. Patients were asked to answer the SF-12 before treatment and 
during follow-up. No statistically significant decrease in any of the measured HC was found 
either at first or last follow-up1. At first follow-up, six months after treatment delivery, bodily 
pain (BP) significantly improved compared to the pretreatment status (p = 0.04)1. Moreover, 
there was a trend towards improvement in mental health (MH), which failed to reach 
significance (p = 0.08)1. The only decrease in absolute HC values was related to role physical 
(RP) but was not significant (p = 0.31)1. Analysis of the SF-12 outcomes at the last follow-up, 
after a median of 38 months, showed no significant changes in any of the eight HC1. Yet, trends 
towards improvements in RP and vitality (VT) were seen (p = 0.06 and p = 0.08)1. To conclude, 
the first publication proved the safety and efficacy of single-session RRS for GJTs in a single-
center analysis. LC rates and symptom control were high, whereas no severe complications 
or treatment-related mortality had been observed1. Finally, the study showed that patients’ 
Qol remains stable or even improves after treatment delivery1. 
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Publication II 
The second publication had the objective to verify the initial findings of the single-center study 
with a larger sample size. Additionally, further objectives included the investigation of 
prognostic factors for symptom control and tumor volume decrease. Finally, a review of the 
radiosurgical literature regardless of the utilized radiosurgical technique (GK, CK, LINAC) was 
conducted. Given the epidemiology of GJTs, only a multicenter study was able to provide 
these insights and to account for biases given the single-center design of the first study. Besides 
the European Cyberknife Center, five more dedicated centers in Germany participated in the 
multicenter study, namely Berlin, Cologne, Erfurt, Soest and Göppingen2. As the role of 
fractionation in RS for GJTs is unclear, the data of patients with multisession RRS were 
included in the second publication to enhance the total sample size and to investigate the 
potential effects of fractionated treatments. Patients undergoing RRS up to a total of five 
fractions were eligible for enrollment. Usually, larger GJTs are treated in up to five sessions 
with good success46-49.  
In the second publication, a total of 101 patients from six centers and their outcomes were 
analyzed2. Sixty-two of them received their primary treatment with RRS2. With a median 
follow-up of 35 months, the follow-up was slightly shorter in comparison with the single-
center analysis1,2. Yet, comparable results in regard to LC and symptom control were 
observed2. The overall LC at last follow-up was 99%2. The posttreatment tumor volume was 
found to be significantly smaller at last follow-up for primarily and secondarily treated tumors 
as well as all patients2. Notably, only one patient had experienced a progressive disease (PD), 
the same case which was previously included in the single-center analysis1,2. No patients from 
centers outside of Munich reported cases of PD. The majority of included patients suffering 
from pretreatment deficits, 89 of 96, had stable symptoms or experienced clinical 
improvements after treatment delivery2. A total of five patients did not report symptoms at 
the time of treatment delivery and remained stable during their follow-up2. Only 13 patients 
were treated in up to five sessions2. Given this small number of patients treated with more 
than one fraction, no dedicated comparisons with single-session treatments in regard to LC 
and symptom control were conducted.  
To investigate prognostic factors for posttreatment tumor volume reduction, toxicity and 
symptom improvement, linear and logistic regression analyses were performed. Pretreatment 
tumor volume was found to be a significant predictor of posttreatment tumor volume change 
(measured in cubic centimeters). Besides, no predictors for symptom improvement and 
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toxicity have been identified2. Only a few studies have investigated prognostic factors for GJT 
treatment outcomes so far2,50-56. One report identified that a higher number of isocenters for 
GK-based RS and the absence of trigeminal nerve dysfunctions at treatment correlate with 
progression-free tumor survival50. A study from 2017 showed that a higher marginal dose is 
associated with an increased risk of tumor progession55. For symptom control or pretreatment 
deficit improvements, one study found in a univariate analysis that pretreatment cranial nerve 
disorders are associated with lowered chances of posttreatment symptom improvement51. 
Moreover, prior surgical resection was shown to correlate with symptom persistence when 
compared to non-surgical patients56. Overall, reliable and reproducible prognostic factors 
remain unknown and hinder the development of consensus guidelines for GJT patients.  
Since a comprehensive review for RRS in the management of GJTs was already completed in 
the first publication, the second study had the objective of analyzing the radiosurgical literature 
since 2000, regardless of the chosen treatment modality1,2. Through a PubMed-based literature 
research, 29 studies reporting the radiosurgical primary and secondary treatment of GJTs 
were identified and analyzed2,39,46,50-77. Most of the radiosurgical reports included patients 
undergoing GK-based RS2. Moreover, most patients included in the analyzed studies received 
single-session RS as their primary treatment2. Reported LC rates were high, with a minority 
of patients suffering from complications after treatment2. Ultimately, RS led to symptom 
control or pretreatment deficit improvements in most patients. Overall, the results of the 
literature review were in agreement with the findings of the first and second publication1,2. No 
evidence was found that RRS might be inferior to GK- or LINAC-based RS2. 
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Discussion 
This cumulative dissertation had the objective of defining the role of RRS in the management 
of GJTs. The first publication was the largest investigating single-session RRS for GJTs and the 
first to report standardized Qol analyses before and after treatment with RS1. The second 
publication comprised the second-largest radiosurgical series of patients treated for GJTs and 
the third to use a multicenter design for GJT RS2. The results of both studies showed RRS to 
be safe and effective for the primary and secondary treatment of GJTs1,2. These findings are 
comparable to the radiosurgical literature available and suggest that RRS may be considered 
for the primary and secondary treatment for the majority of GJTs1,2. Especially the stable and 
partially improving Qol results after treatment delivery are vital to improve clinical decision-
making and to guide GJT patients who are eligible to undergo surgical tumor resection or 
radiotherapy. It is important to note that surgical treatment options yield a larger treatment-
related morbidity than RS and radiotherapy but may achieve comparable LC rates19,20,25. 
Nevertheless, surgery is considered to play an essential role for catecholamine-secreting and 
malignant GJTs, as well as for young patients with high life expectancy19,25. In addition, some 
studies have recommended surgical resection for small to medium-sized GJTs78-80. In regard to 
the available literature, RS, including RRS, seems to have a slightly better LC than radiotherapy 
and may cause fewer complications, irrespective of the treatment modality utilized (GK, CK, 
LINAC)2,19,25. However, radiotherapy may be used for GJT patients if RS is not available19. Both 
techniques have advantageous risk profiles compared to surgery and the risk of radiation-
induced malignancies and persistent complications is low19,25,81. Given the lack of reports 
investigating multidisciplinary treatments, the dedicated roles of radiotherapy, RS, surgery and 
combinations of them remain unclear. 
Taking the median follow-up durations of both publications into consideration, more analyses 
with longer follow-up are needed to determine whether the present findings are long-lasting. 
This is particularly important as GJT recurrences can occur many years after treatment 
delivery19,25,38,82,83. Other limitations of both publications include their retrospective nature, 
thereby increasing the risk for selection and reporting biases, lack of histopathological 
diagnosis in the majority of patients and lack of detailed follow-up information for 
pretreatment deficits, as well as classification systems (e. g. House-Brackmann, audiogram, 
Fisch classification). Despite these limitations, this dissertation, including both publications, 
provides evidence that RRS can play a central role in the management of GJTs, especially for 
patients not suitable for surgical resection. To evaluate not only the role of RRS but also RS 
further, prospective studies are needed, addressing the inherent limitations of the publications 
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described and reviewed here. Patient-reported outcomes, like Qol analyses should be 
implemented to guide further decision-making. Finally, trials comparing surgery with RS or 
radiotherapy might help to establish consensus guidelines for GJT management, which would 
ultimately advance clinical care for patients. 
 
Conclusion 
Both studies showed RRS to be a safe and efficient treatment option for GJTs. The results of 
the primary and secondary treatment for GJTs are consistent, while the Qol of patients 
remains stable and tends to improve after treatment delivery. RRS achieves comparable results 
to other radiosurgical techniques while demonstrating a low rate of treatment-associated 
complications. RRS may be considered as a primary treatment option for most GJTs. 
 
Summary 
Glomus jugulare tumors (GJTs) are rare head and neck paragangliomas originating from the 
paraganglia of the jugular bulb. These tumors may cause significant morbidity, a decline in 
patients’ quality of life (Qol) and remain challenging to treat surgically given their localization 
and vascularization. Thus, non-invasive treatment options can be advantageous, not only for 
patients not suitable for surgical resection. Radiosurgery (RS) for GJTs has been of recent 
interest due to its efficacy and safety. So far, only limited data is available on the use of image-
guided robotic radiosurgery (RRS) for treatment of GJTs. In this cumulative dissertation, the 
role of RRS in the management of GJTs was investigated with two studies, one single-center 
study and a subsequent multicenter trial. Results of both analyses, including a comprehensive 
literature review, showed RRS to be an effective and safe tool for the primary and secondary 
treatment of GJTs. Local control (LC) and symptom control rates are high and comparable to 
the radiosurgical results reported in the literature. Moreover, Qol analyses of SF-12 data 
showed that patients have a stable or even improved Qol after RRS treatment delivery. 
Pretreatment tumor volume had a significant impact on posttreatment tumor volume 
reduction. No predictive factors for symptom improvement and toxicity were found. Overall, 
the results of both studies suggest RRS to be a primary treatment option for most GJTs. 
 
Glomus jugulare Tumoren (GJT) sind seltene Paragangliome der Schädelbasis, welche aus den 
(para)sympathischen Zellen im Bereich des Bulbus venae jugularis entspringen. Aufgrund ihrer 
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Lokalisation können diese Tumoren starke Beschwerden und eine eingeschränkte 
Lebensqualität bei betroffenen Patienten herbeiführen. Aufgrund dessen und durch die 
ausgeprägte Vaskularisation sind die Tumoren nach wie vor chirurgisch nur eingeschränkt zu 
behandeln. Folglich können nicht-invasive Behandlungsoptionen von Vorteil sein, vor allem für 
Patienten, die sich keiner Operation unterziehen können bzw. wollen. Aufgrund ihrer 
Effektivität und Sicherheit bei der Behandlung von GJT ist die Radiochirurgie zunehmend in 
den Fokus des Interesses gerückt. Derzeit gibt es nur eingeschränkte Daten zum Gebrauch 
der bildgeführten robotischen Radiochirurgie zur Behandlung von GJT. In dieser kumulativen 
Dissertation wurde der Stellenwert der bildgeführten robotischen Radiochirurgie für die 
Behandlung von GJT im Rahmen zweier Studien untersucht – zuerst in einer monozentrischen 
Analyse, in der Folge anhand einer multizentrischen Studie. Die Ergebnisse beider 
Untersuchungen einschließlich einer umfassenden Literaturanalyse zeigen, dass die robotische 
Radiochirurgie eine effektive und sichere Behandlungsmethode sowohl für die primäre, als 
auch sekundäre Behandlung von GJT darstellt. Die Lokal- als auch Symptomkontrolle sind hoch 
und vergleichbar mit den radiochirurgischen Ergebnissen, die in der bisherigen Literatur 
beschrieben sind. Des Weiteren zeigten die Analysen der SF-12 Daten, dass Patienten nach 
der Behandlung eine stabile oder sogar verbesserte Lebensqualität genießen. Das 
prätherapeutische Tumorvolumen hatte signifikanten Einfluss auf den posttherapeutischen 
Tumorvolumenrückgang. Prädiktive Faktoren zur Beschwerdebesserung und Toxizität wurden 
nicht gefunden. Die Ergebnisse beider Studien legen nahe, dass die robotische Radiochirurgie 
eine primäre Behandlungsoption für den Großteil der GJT darstellen kann. 
  




Single-Session Image-Guided Robotic Radiosurgery and Quality of Life for Glomus Jugulare Tumors1 
Ehret F, Kufeld M, Fürweger C, et al.  










Image-Guided Robotic Radiosurgery for Glomus Jugulare Tumors – Multicenter Experience and 
Review of the Literature2 
Ehret F, Kufeld M, Fürweger C, et al.  
Head & Neck. 2020;1–13. https://doi.org/10.1002/hed.26439 
PMID: 32851752 
  




1. Ehret F, Kufeld M, Fürweger C, et al. Single-session image-guided robotic radiosurgery and 
quality of life for glomus jugulare tumors. Head & neck 2020; 42(9): 2421-30. 
2. Ehret F, Kufeld M, Fürweger C, et al. Image-guided robotic radiosurgery for glomus jugulare 
tumors-Multicenter experience and review of the literature. Head & neck 2020. 
3. DeLellis RA. Pathology and genetics of tumours of endocrine organs: IARC; 2004. 
4. Favier J, Amar L, Gimenez-Roqueplo AP. Paraganglioma and phaeochromocytoma: from 
genetics to personalized medicine. Nat Rev Endocrinol 2015; 11(2): 101-11. 
5. Guild SR. The glomus jugulare, a nonchromaffin paraganglion, in man. The Annals of otology, 
rhinology, and laryngology 1953; 62(4): 1045-71; concld. 
6. Bickerstaff ER, Howell JS. The neurological importance of tumours of the glomus jugulare. 
Brain : a journal of neurology 1953; 76(4): 576-93. 
7. Moffat DA, Hardy DG. Surgical management of large glomus jugulare tumours: infra- and 
trans-temporal approach. J Laryngol Otol 1989; 103(12): 1167-80. 
8. Gulya AJ. The glomus tumor and its biology. The Laryngoscope 1993; 103(11 Pt 2 Suppl 60): 7-
15. 
9. Havekes B, van der Klaauw AA, Hoftijzer HC, et al. Reduced quality of life in patients with 
head-and-neck paragangliomas. Eur J Endocrinol 2008; 158(2): 247-53. 
10. van Hulsteijn LT, Louisse A, Havekes B, et al. Quality of life is decreased in patients with 
paragangliomas. Eur J Endocrinol 2013; 168(5): 689-97. 
11. Patel NS, Link MJ, Tombers NM, Pollock BE, Carlson ML. Quality of Life in Jugular 
Paraganglioma Following Radiosurgery. Otol Neurotol 2019; 40(6): 820-5. 
12. Lee JH, Barich F, Karnell LH, et al. National Cancer Data Base report on malignant 
paragangliomas of the head and neck. Cancer 2002; 94(3): 730-7. 
13. Wolter NE, Adil E, Irace AL, et al. Malignant glomus tumors of the head and neck in children 
and adults: Evaluation and management. The Laryngoscope 2017; 127(12): 2873-82. 
14. Folpe AL, Fanburg-Smith JC, Miettinen M, Weiss SW. Atypical and malignant glomus tumors: 
analysis of 52 cases, with a proposal for the reclassification of glomus tumors. Am J Surg Pathol 2001; 
25(1): 1-12. 
15. Brathwaite CD, Poppiti RJ, Jr. Malignant glomus tumor. A case report of widespread 
metastases in a patient with multiple glomus body hamartomas. Am J Surg Pathol 1996; 20(2): 233-8. 
16. Hamidi O, Young WF, Jr., Iñiguez-Ariza NM, et al. Malignant Pheochromocytoma and 
Paraganglioma: 272 Patients Over 55 Years. J Clin Endocrinol Metab 2017; 102(9): 3296-305. 
17. Lundgren N. Tympanic body tumours in the middle ear; tumours of carotid body type. Acta 
oto-laryngologica 1949; 37(4): 367-79, illust. 
18. Hallett JW, Jr., Nora JD, Hollier LH, Cherry KJ, Jr., Pairolero PC. Trends in neurovascular 
complications of surgical management for carotid body and cervical paragangliomas: a fifty-year 
experience with 153 tumors. Journal of vascular surgery 1988; 7(2): 284-91. 
19. Lieberson RE, Adler JR, Soltys SG, Choi C, Gibbs IC, Chang SD. Stereotactic radiosurgery as 
the primary treatment for new and recurrent paragangliomas: is open surgical resection still the 
treatment of choice? World neurosurgery 2012; 77(5-6): 745-61. 
20. Gottfried ON, Liu JK, Couldwell WT. Comparison of radiosurgery and conventional surgery 
for the treatment of glomus jugulare tumors. Neurosurgical focus 2004; 17(2): E4. 
21. Bacciu A, Medina M, Ait Mimoune H, et al. Lower cranial nerves function after surgical 
treatment of Fisch Class C and D tympanojugular paragangliomas. European Archives of Oto-Rhino-
Laryngology 2015; 272(2): 311-9. 
22. Wanna GB, Sweeney AD, Haynes DS, Carlson ML. Contemporary management of jugular 
paragangliomas. Otolaryngologic clinics of North America 2015; 48(2): 331-41. 
23. Kaylie DM, O'Malley M, Aulino JM, Jackson CG. Neurotologic surgery for glomus tumors. 
Otolaryngologic clinics of North America 2007; 40(3): 625-49, x. 
24. van der Mey AG, Frijns JH, Cornelisse CJ, et al. Does intervention improve the natural 
course of glomus tumors? A series of 108 patients seen in a 32-year period. The Annals of otology, 
rhinology, and laryngology 1992; 101(8): 635-42. 
- 20 - 
 
25. Suarez C, Rodrigo JP, Bodeker CC, et al. Jugular and vagal paragangliomas: Systematic study 
of management with surgery and radiotherapy. Head & neck 2013; 35(8): 1195-204. 
26. Huy PT, Kania R, Duet M, Dessard-Diana B, Mazeron JJ, Benhamed R. Evolving concepts in 
the management of jugular paraganglioma: a comparison of radiotherapy and surgery in 88 cases. Skull 
Base 2009; 19(1): 83-91. 
27. Krych AJ, Foote RL, Brown PD, Garces YI, Link MJ. Long-term results of irradiation for 
paraganglioma. Int J Radiat Oncol Biol Phys 2006; 65(4): 1063-6. 
28. Pryzant RM, Chou JL, Easley JD. Twenty year experience with radiation therapy for temporal 
bone chemodectomas. Int J Radiat Oncol Biol Phys 1989; 17(6): 1303-7. 
29. Schild SE, Foote RL, Buskirk SJ, et al. Results of radiotherapy for chemodectomas. Mayo Clin 
Proc 1992; 67(6): 537-40. 
30. Cole JM, Beiler D. Long-term results of treatment for glomus jugulare and glomus vagale 
tumors with radiotherapy. The Laryngoscope 1994; 104(12): 1461-5. 
31. de Jong AL, Coker NJ, Jenkins HA, Goepfert H, Alford BR. Radiation therapy in the 
management of paragangliomas of the temporal bone. Am J Otol 1995; 16(3): 283-9. 
32. Pemberton LS, Swindell R, Sykes AJ. Radical radiotherapy alone for glomus jugulare and 
tympanicum tumours. Oncol Rep 2005; 14(6): 1631-3. 
33. Hinerman RW, Amdur RJ, Morris CG, Kirwan J, Mendenhall WM. Definitive radiotherapy in 
the management of paragangliomas arising in the head and neck: a 35-year experience. Head & neck 
2008; 30(11): 1431-8. 
34. Lassen-Ramshad Y, Ozyar E, Alanyali S, et al. Paraganglioma of the head and neck region, 
treated with radiation therapy, a Rare Cancer Network study. Head & neck 2019; 41(6): 1770-6. 
35. Lightowlers S, Benedict S, Jefferies SJ, et al. Excellent local control of paraganglioma in the 
head and neck with fractionated radiotherapy. Clin Oncol (R Coll Radiol) 2010; 22(5): 382-9. 
36. van Hulsteijn LT, Corssmit EP, Coremans IE, Smit JW, Jansen JC, Dekkers OM. Regression 
and local control rates after radiotherapy for jugulotympanic paragangliomas: systematic review and 
meta-analysis. Radiother Oncol 2013; 106(2): 161-8. 
37. Kida Y, Kobayashi T, Tanaka T, Oyama H, Niwa M. [A new strategy for the treatment of 
jugular foramen tumors using radiosurgery]. No shinkei geka Neurological surgery 1995; 23(8): 671-5. 
38. Guss ZD, Batra S, Limb CJ, et al. Radiosurgery of glomus jugulare tumors: a meta-analysis. Int 
J Radiat Oncol Biol Phys 2011; 81(4): e497-502. 
39. Patel NS, Carlson ML, Pollock BE, et al. Long-term tumor control following stereotactic 
radiosurgery for jugular paraganglioma using 3D volumetric segmentation. J Neurosurg 2018: 1-9. 
40. Adler JR, Jr., Chang SD, Murphy MJ, Doty J, Geis P, Hancock SL. The Cyberknife: a frameless 
robotic system for radiosurgery. Stereotactic and functional neurosurgery 1997; 69(1-4 Pt 2): 124-8. 
41. Galland-Girodet S, Maire JP, De-Mones E, et al. The role of radiation therapy in the 
management of head and neck paragangliomas: impact of quality of life versus treatment response. 
Radiother Oncol 2014; 111(3): 463-7. 
42. Patel NS, Link MJ, Driscoll CLW, Pollock BE, Lohse CM, Carlson ML. Hearing Outcomes 
After Stereotactic Radiosurgery for Jugular Paraganglioma. Otol Neurotol 2018; 39(1): 99-105. 
43. Ware J, Jr., Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of 
scales and preliminary tests of reliability and validity. Medical care 1996; 34(3): 220-33. 
44. Gandek B, Ware JE, Aaronson NK, et al. Cross-validation of item selection and scoring for 
the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of 
Life Assessment. J Clin Epidemiol 1998; 51(11): 1171-8. 
45. Jenkinson C, Layte R, Jenkinson D, et al. A shorter form health survey: can the SF-12 
replicate results from the SF-36 in longitudinal studies? J Public Health Med 1997; 19(2): 179-86. 
46. Hurmuz P, Cengiz M, Ozyigit G, et al. Robotic stereotactic radiosurgery in patients with 
unresectable glomus jugulare tumors. Technology in cancer research & treatment 2013; 12(2): 109-13. 
47. Chun SG, Nedzi LA, Choe KS, et al. A retrospective analysis of tumor volumetric responses 
to five-fraction stereotactic radiotherapy for paragangliomas of the head and neck (glomus tumors). 
Stereotactic and functional neurosurgery 2014; 92(3): 153-9. 
48. Tuniz F, Soltys SG, Choi CY, et al. Multisession cyberknife stereotactic radiosurgery of large, 
benign cranial base tumors: preliminary study. Neurosurgery 2009; 65(5): 898-907; discussion  
- 21 - 
 
49. Tosun I, Atalar B, Sahin B, et al. Robotic radiosurgery of head and neck paragangliomas: a 
single institution experience. Asia-Pacific journal of clinical oncology 2018; 14(2): e3-e7. 
50. Sheehan JP, Tanaka S, Link MJ, et al. Gamma Knife surgery for the management of glomus 
tumors: a multicenter study. J Neurosurg 2012; 117(2): 246-54. 
51. Sallabanda K, Barrientos H, Isernia Romero DA, et al. Long-term outcomes after 
radiosurgery for glomus jugulare tumors. Tumori 2018; 104(4): 300-6. 
52. Ibrahim R, Ammori MB, Yianni J, Grainger A, Rowe J, Radatz M. Gamma Knife radiosurgery 
for glomus jugulare tumors: a single-center series of 75 cases. J Neurosurg 2017; 126(5): 1488-97. 
53. Gandia-Gonzalez ML, Kusak ME, Moreno NM, Sarraga JG, Rey G, Alvarez RM. 
Jugulotympanic paragangliomas treated with Gamma Knife radiosurgery: a single-center review of 58 
cases. J Neurosurg 2014; 121(5): 1158-65. 
54. Sharma M, Meola A, Bellamkonda S, et al. Long-Term Outcome Following Stereotactic 
Radiosurgery for Glomus Jugulare Tumors: A Single Institution Experience of 20 Years. Neurosurgery 
2018; 83(5): 1007-14. 
55. Winford TW, Dorton LH, Browne JD, Chan MD, Tatter SB, Oliver ER. Stereotactic 
Radiosurgical Treatment of Glomus Jugulare Tumors. Otol Neurotol 2017; 38(4): 555-62. 
56. Wakefield DV, Venable GT, VanderWalde NA, et al. Comparative Neurologic Outcomes of 
Salvage and Definitive Gamma Knife Radiosurgery for Glomus Jugulare: A 20-Year Experience. J 
Neurol Surg B Skull Base 2017; 78(3): 251-5. 
57. Tripathi M, Rekhapalli R, Batish A, et al. Safety and Efficacy of Primary Multisession Dose 
Fractionated Gamma Knife Radiosurgery for Jugular Paragangliomas. World neurosurgery 2019; 131: 
e136-e48. 
58. Gigliotti MJ, Hasan S, Liang Y, Chen D, Fuhrer R, Wegner RE. A 10-year experience of linear 
accelerator-based stereotactic radiosurgery/radiotherapy (SRS/SRT) for paraganglioma: A single 
institution experience and review of the literature. J Radiosurg SBRT 2018; 5(3): 183-90. 
59. Hafez RFA, Morgan MS, Fahmy OM, Hassan HT. Long-term effectiveness and safety of 
stereotactic gamma knife surgery as a primary sole treatment in the management of glomus jagulare 
tumor. Clin Neurol Neurosurg 2018; 168: 34-7. 
60. Dobberpuhl MR, Maxwell S, Feddock J, St Clair W, Bush ML. Treatment Outcomes for Single 
Modality Management of Glomus Jugulare Tumors With Stereotactic Radiosurgery. Otology & 
neurotology : official publication of the American Otological Society, American Neurotology Society [and] 
European Academy of Otology and Neurotology 2016; 37(9): 1406-10. 
61. El Majdoub F, Hunsche S, Igressa A, Kocher M, Sturm V, Maarouf M. Stereotactic LINAC-
Radiosurgery for Glomus Jugulare Tumors: A Long-Term Follow-Up of 27 Patients. PLoS One 2015; 
10(6): e0129057. 
62. Sager O, Beyzadeoglu M, Dincoglan F, et al. Evaluation of linear accelerator-based 
stereotactic radiosurgery in the management of glomus jugulare tumors. Tumori 2014; 100(2): 184-8. 
63. de Andrade EM, Brito JR, Mario SD, de Melo SM, Benabou S. Stereotactic radiosurgery for 
the treatment of Glomus Jugulare Tumors. Surg Neurol Int 2013; 4(Suppl 6): S429-35. 
64. Chen PG, Nguyen JH, Payne SC, Sheehan JP, Hashisaki GT. Treatment of glomus jugulare 
tumors with gamma knife radiosurgery. The Laryngoscope 2010; 120(9): 1856-62. 
65. Genc A, Bicer A, Abacioglu U, Peker S, Pamir MN, Kilic T. Gamma knife radiosurgery for the 
treatment of glomus jugulare tumors. J Neurooncol 2010; 97(1): 101-8. 
66. Navarro Martin A, Maitz A, Grills IS, et al. Successful treatment of glomus jugulare tumours 
with gamma knife radiosurgery: clinical and physical aspects of management and review of the 
literature. Clin Transl Oncol 2010; 12(1): 55-62. 
67. Ganz JC, Abdelkarim K. Glomus jugulare tumours: certain clinical and radiological aspects 
observed following Gamma Knife radiosurgery. Acta Neurochir (Wien) 2009; 151(5): 423-6. 
68. Miller JP, Semaan M, Einstein D, Megerian CA, Maciunas RJ. Staged Gamma Knife 
radiosurgery after tailored surgical resection: a novel treatment paradigm for glomus jugulare tumors. 
Stereotactic and functional neurosurgery 2009; 87(1): 31-6. 
69. Sharma MS, Gupta A, Kale SS, Agrawal D, Mahapatra AK, Sharma BS. Gamma knife 
radiosurgery for glomus jugulare tumors: therapeutic advantages of minimalism in the skull base. 
Neurol India 2008; 56(1): 57-61. 
- 22 - 
 
70. Lim M, Bower R, Nangiana JS, Adler JR, Chang SD. Radiosurgery for glomus jugulare tumors. 
Technology in cancer research & treatment 2007; 6(5): 419-23. 
71. Bitaraf MA, Alikhani M, Tahsili-Fahadan P, et al. Radiosurgery for glomus jugulare tumors: 
experience treating 16 patients in Iran. J Neurosurg 2006; 105 Suppl: 168-74. 
72. Feigl GC, Horstmann GA. Intracranial glomus jugulare tumors: volume reduction with 
Gamma Knife surgery. J Neurosurg 2006; 105 Suppl: 161-7. 
73. Gerosa M, Visca A, Rizzo P, Foroni R, Nicolato A, Bricolo A. Glomus jugulare tumors: the 
option of gamma knife radiosurgery. Neurosurgery 2006; 59(3): 561-9; discussion -9. 
74. Poznanovic SA, Cass SP, Kavanagh BD. Short-term tumor control and acute toxicity after 
stereotactic radiosurgery for glomus jugulare tumors. Otolaryngol Head Neck Surg 2006; 134(3): 437-
42. 
75. Feigenberg SJ, Mendenhall WM, Hinerman RW, Amdur RJ, Friedman WA, Antonelli PJ. 
Radiosurgery for paraganglioma of the temporal bone. Head & neck 2002; 24(4): 384-9. 
76. Eustacchio S, Trummer M, Unger F, Schrottner O, Sutter B, Pendl G. The role of Gamma 
Knife radiosurgery in the management of glomus jugular tumours. Acta Neurochir Suppl 2002; 84: 91-
7. 
77. Saringer W, Khayal H, Ertl A, Schoeggl A, Kitz K. Efficiency of gamma knife radiosurgery in 
the treatment of glomus jugulare tumors. Minim Invasive Neurosurg 2001; 44(3): 141-6. 
78. Forest JA, 3rd, Jackson CG, McGrew BM. Long-term control of surgically treated glomus 
tympanicum tumors. Otol Neurotol 2001; 22(2): 232-6. 
79. Jackson CG, Glasscock ME, 3rd, Harris PF. Glomus Tumors. Diagnosis, classification, and 
management of large lesions. Arch Otolaryngol 1982; 108(7): 401-10. 
80. Lenarz T, Plinkert PK. [Glomus tumors of the temporal bone--surgical concept and results]. 
Laryngorhinootologie 1992; 71(3): 149-57. 
81. Pollock BE, Link MJ, Stafford SL, Parney IF, Garces YI, Foote RL. The Risk of Radiation-
Induced Tumors or Malignant Transformation After Single-Fraction Intracranial Radiosurgery: Results 
Based on a 25-Year Experience. Int J Radiat Oncol Biol Phys 2017; 97(5): 919-23. 
82. Pollock BE, Foote RL. The evolving role of stereotactic radiosurgery for patients with skull 
base tumors. J Neurooncol 2004; 69(1-3): 199-207. 
83. Shapiro S, Kellermeyer B, Ramadan J, Jones G, Wiseman B, Cassis A. Outcomes of Primary 
Radiosurgery Treatment of Glomus Jugulare Tumors: Systematic Review With Meta-analysis. Otol 
Neurotol 2018; 39(9): 1079-87. 
 
  




I would like to express my deep gratitude to my supervisors – Prof. Dr. Alexander Muacevic 
and Dr. Markus Kufeld – for their patient guidance, enthusiastic encouragement and useful 
feedback on this work. 
 
My sincere thanks go to my other supervisors – Prof. Dr. Christian Schichor and PD Dr. 
John-Martin Hempel –, all co-authors and participating centers for the productive 
collaboration. 
 
I would also like to extend my appreciation to the team of the European Cyberknife Center 
Munich for their tremendous support and help. 
 
Finally, I thank my parents for their continuous support throughout my life. This dissertation 
stands as a testament to their unconditional love and generosity. 
 
This work was supported by the Munich Medical Research School, Ludwig-Maximilians-
University Munich. 
  



































- 25 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
